News
3h
Live Science on MSNExperimental treatment for high cholesterol edits DNA in the body to reduce LDLAn experimental treatment called VERVE-102 lowers the amount of "bad" cholesterol in the blood of people with specific ...
We came across a bullish thesis on Verve Therapeutics, Inc. on Stock Region Research’s Substack by Stock Region. In this ...
Shares of Verve Therapeutics skyrocketed 75% Tuesday morning after Eli Lilly announced that it would acquire the gene-editing startup for about $1.3 billion.
Donald Trump's proposed 200% tariffs can squeeze the profit margins of pharma companies, but LLY is poised to "benefit" ...
Eli Lilly will acquire gene-editing startup Verve Therapeutics for up to $1.3 billion, the companies said on Tuesday, ...
Verve Therapeutics’ stock was rallying by a record 80% on Eli Lilly’s premium purchase price for the drug-development company.
Eli Lilly LLY -0.47% agreed to acquire Verve Therapeutics VERV 0.45% for about $1 billion upfront, adding a potential treatment for cardiovascular disease to its portfolio. Under the agreement ...
Eli Lilly's (LLY) $1.3B Verve Therapeutics (VERV) acquisition offers investors a 70%+ premium. See why I think this deal is beneficial to both companies.
Shares of Verve Therapeutics (NASDAQ: VERV) were skyrocketing 75.7% higher as of 10:50 a.m. ET on Tuesday. Eli Lilly (NYSE: LLY) and Verve Therapeutics announced a "definitive agreement for Lilly ...
Verve Therapeutics, Inc. (Nasdaq: VERV) is a clinical-stage company developing a new class of genetic medicines for cardiovascular disease with the potential to transform treatment from chronic ...
Lilly to acquire Verve Therapeutics to advance one-time treatments for people with high cardiovascular risk Provided by PR Newswire Jun 17, 2025, 10:45:00 AM ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results